The The use of poly-L-lactic acid- SCA treatment for HIV-related oromaxillofacial lipoatrophy in Brazil: expert panel recommendations
DOI:
https://doi.org/10.5327/2525-5711.457Palavras-chave:
HIV, Quality of life, Antiretroviral Therapy, Highly Active, Patient SatisfactionResumo
Objective: To provide expert panel recommendations regarding the use of poly-L-lactic acid-SCA (PLLA-SCA) for the treatment of Human Immunodeficiency Virus – HIV - related oromaxillofacial lipoatrophy in Brazil. Methods: A multidisciplinary expert panel comprising five dermatologists and one infectious disease specialist convened an in-person meeting to discuss the contemporary patient journey, clinical practices, treatment approaches, and safety considerations related to PLLA-SCA in HIV-related facial lipoatrophy. The recommendations were based on the clinical experience of the panel members and informed by the current literature. Results: The panel considered HIV-related oromaxillofacial lipoatrophy an important psychosocial condition negatively affecting quality of life, self-image, and social interactions. PLLA-SCA was considered an effective and well-tolerated regenerative biostimulator for facial volume restoration and improvement of facial contour and skin quality in patients living with HIV. The recommendations included preferential application of PLLA-SCA to the lateral face, including temples, pre-auricular, and mandibular regions, while avoiding areas previously treated with permanent implants. The panel also emphasized individualized treatment planning, safety assessment, and multidisciplinary follow-up. Conclusion: Based on the available literature and the collective clinical experience of the panel members, PLLA-SCA may represent a safe and effective treatment option for HIV-related oromaxillofacial lipoatrophy. These expert panel recommendations provide practical clinical considerations to support individualized treatment planning and optimization of aesthetic and psychosocial outcomes in patients living with HIV.
Referências
1. Casseb J, Fonseca LA, Veiga AP, de Almeida A, Bueno A, Ferez AC, et al. AIDS incidence and mortality in a hospital-based cohort of HIV-1-seropositive patients receiving highly active antiretroviral therapy in São Paulo, Brazil. AIDS Patient Care STDS. 2003;17(9):447-52.
2. Benzaken AS, Pereira GFM, Costa L, Tanuri A, Santos AF, Soares MA. Antiretroviral treatment, government policy and economy of HIV/AIDS in Brazil: is it time for HIV cure in the country? AIDS Res Ther. 2019;16(1):19.
3. Wu AW, Wansom T, Huang IC, CoFrancesco J Jr, Conant MA, Sarwer DB. The Facial Appearance Inventory: Development and Preliminary Evidence for Reliability and Validity in People with HIV and Lipoatrophy. Aesthet Surg J. 2016;36(7):842-51.
4. Giralt, M., Domingo, P., Quesada-López, T., Cereijo, R., & Villarroya, F. Lipodystrophy in HIV: Evolving Challenges and Unresolved Questions. International Journal of Molecular Sciences, 2025; 26(14), 6546.https://doi.org/10.3390/ijms26146546
5. Strand A, Wolters M. HIV-related lipodystrophy and facial lipoatrophy: the role of Restylane SubQ in reversing facial wasting. Aesthet Surg J. 2006;26(1S):S35-40.
6. Engelhard P. Correction options for lipoatrophy in HIV-infected patients. AIDS Patient Care STDS. 2006;20(3):151-60.
7. Soares FM, Costa IM. Treatment of HIV-associated facial lipoatrophy: impact on infection progression assessed by viral load and CD4 count. An Bras Dermatol. 2013;88(4):570-7.
8. Guaraldi G, Murri R, Orlando G, Giovanardi C, Squillace N, Vandelli M, et al. Severity of lipodystrophy is associated with decreased health-related quality of life. AIDS Patient Care STDS. 2008;22(7):577-85.
9. Alencastro PR, Barcellos NT, Wolff FH, Ikeda ML, Schuelter-Trevisol F, Brandão AB, et al. People living with HIV on ART have accurate perception of lipodystrophy signs: a cross-sectional study. BMC Res Notes. 2017;10(1):40.
10. ANVISA. Portaria conjunta nº 01, de 20 de janeiro de 2009. Available at (accessed on December8, 2023):https://bvsms.saude.gov.br/bvs/sas/Links%20finalizados%20SAS%202009/poc0001_20_01_2009.html
11. Brasil. Ministério da Saúde. Tratamento da Lipoatrofia facial: Preenchimento com PMMA. In: Brasil. Ministério da Saúde do Brasil, Departamento de DST, Aids e Hepatites Virais. Manual de Tratamento da Lipoatrofia facial - Recomendações para o preenchimento facial com polimetilmetacrilato em portadores de HIV/AIDS. Brasília: Ministério da Saúde; 2009. p.27-37.
12. Martins WH, Pessôa KVO, Martins MA, Silva MH, Pereira Filho GV, Abreu LC. Facial filling with polymethylmethacrylate in patients with acquired immunodeficiency syndrome. Rev. Bras. Cir. Plást. 2016;31(2):216-228
13. Palm M, Weinkle S, Cho Y, LaTowsky B, Prather H. A Randomized Study on PLLA-SCA Using Higher Dilution Volume and Immediate Use Following Reconstitution. J Drugs Dermatol. 2021;20(7):760-766.
14. Valantin MA, Aubron-Olivier C, Ghosn J, Laglenne E, Pauchard M, Schoen H, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS. 2003;17(17):2471-7.
15. Moyle GJ, Lysakova L, Brown S, Sibtain N, Healy J, Priest C, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med. 2004;5(2):82-7.
16. Moyle GJ, Brown S, Lysakova L, Barton SE. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med. 2006;7(3):181-5.
17. Bassichis B, Blick G, Conant M, Condoluci D, Echavez M, Eviatar J, et al. Injectable poly-L-lactic acid for human immunodeficiency virus-associated facial lipoatrophy: cumulative year 2 interim analysis of an open-label study (FACES). Dermatol Surg. 2012;38(7 Pt 2):1193–205.
18. Mest DR, Humble GM. Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study. Dermatol Surg. 2009b;35 Suppl 1:350-9.
19. Duracinsky M, Leclercq P, Herrmann S, Christen MO, Dolivo M, Goujard C, et al. Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients. BMC Infect Dis. 2014;14:474.
20. Dreezen C, Schrooten W, de Mey I, Goebel FD, Dedes N, Florence E, et al. Int J STD AIDS. 2002;13(6):393-8.
21. Serra MS, Oyafuso LK, Trope BM, Munhoz Leite OH, Ramos-e-Silva M. An index for staging facial lipoatrophy and evaluation of the efficacy of the treatment with polymethylmethacrylate in HIV/AIDS patients: a pilot study. J Eur Acad Dermatol Venereol. 2013;27(8):990-6.
22. Yoshioka MCN. Avaliação do uso do ácido poli-l-láctico no tratamento da lipoatrofia facial associada à terapia antirretroviral em pacientes soropositivos para o vírus da imunodeficiência humana [tese]. São Paulo (BR): Universidade Federal de São Paulo; 2009.
23. Soares LR, Casseb JSDR, Chaba DCDS, Batista LO, Sousa LVA, Fonseca FLA. Self-reported lipodystrophy, nutritional, lipemic profile and its impact on the body image of HIV-1-infected persons, with and without antiretroviral therapy. AIDS Care. 2020;32(10):1317-1322.
24. Mest DR, Humble G. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience. Dermatol Surg. 2006;32(11):1336-45.
25. Jagdeo J, Ho D, Lo A, Carruthers A. A systematic review of filler agents for aesthetic treatment of HIV facial lipoatrophy (FLA). J Am Acad Dermatol. 2015;73(6):1040-54.e14.
26. Mest DR, Humble GM. Duration of correction for human immunodeficiency virus-associated lipoatrophy after retreatment with injectable poly-L-lactic acid. Aesthetic Plast Surg. 2009a;33(4):654-6.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2026 Luiza Keiko Matsuka Oyafuso, Ada Regina Trindade de Almeida, Alessandra Moraes Barros Vieira; Álvaro Furtado da Costa; Danilo Finamor, Leonardo Zacharias Gonçalves, Rafael Tomaz, Cristhine Kamamoto
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
